Studio City Widening Retail Options with Specialty Store “DON DON DONKI” Set to Open on February 2
Offering Authentic Japanese Food and Culture Experience MACAU SAR - Media OutReach Newswire - 29…
2 years ago
MLB Agrees to International Partnership With JTB Corp., Japan’s Largest Travel Agency
JTB Set to Sponsor MLB’s WORLD TOUR, Offer Exclusive Hospitality Packages for Seoul Series TOKYO--(BUSINESS…
2 years ago
Autosilicon Releases 24-Channel Battery Diagnosis IC for Electric Vehicles and Energy Storage Systems
SEOUL, South Korea--(BUSINESS WIRE)--#24ChannelBatteryDiagnosisIC--Autosilicon Inc. has launched 24-channel Battery Diagnosis IC (BDIC) in January for…
2 years ago
SoftBank Ventures Asia is Newly Becoming SBVA
The New SBVA Establishes KRW 200B ($150M) Korea Venture Fund SEOUL, South Korea--(BUSINESS WIRE)--SoftBank Ventures…
2 years ago
AlphaX Officially launches Cryptocurrency Exchange Platform
ADELAIDE, AUSTRALIA - Media OutReach Newswire - 29 January 2024 – AlphaX, a cryptocurrency exchange…
2 years ago
Booi India review – Casino games | Bonus | Register
Booi India: A Journey through the Evolution of Online Betting With the goal of giving…
2 years ago
AIC’s Break the Silver Ceiling campaign drew support from over 700
SINGAPORE - Media OutReach Newswire - 28 January 2024 - In a show of unity…
2 years ago
Patient Safety Movement Foundation’s Mid-Year Meeting Charts Course for Global Patient Safety Initiatives in 2024
IRVINE, Calif.--(BUSINESS WIRE)--The Patient Safety Movement Foundation (PSMF) convened its annual Mid-Year Event to discuss…
2 years ago
Vietnam Construction Industry Report 2023: Sector Growth and Pipeline Analysis to 2027 – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Vietnam Construction Market Size, Trends, and Forecasts by Sector - Commercial, Industrial, Infrastructure,…
2 years ago
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free…
2 years ago